Navidea Biopharmaceuticals has launched its Lymphoseek (technetium Tc 99m tilmanocept) Injection in the US.
The injection is used in lymphatic mapping procedures that help in the diagnostic evaluation of potential cancer spread for patients with breast cancer and melanoma.
The US Food and Drug Administration (FDA) had approved Lymphoseek injection in March 2013.
As part of Navidea's US distribution partnership, Cardinal Health will sell and distribute Lymphoseek to health care professionals.
Navidea president and CEO Mark Pykett said that the commercialization of Lymphoseek in the US marks a milestone for Navidea, and the company is pleased to deliver this diagnostic imaging agent to patients with breast cancer and melanoma.
"With Cardinal Health's extensive reach and pre-eminent radiopharmacy network, combined with our own medical education activities now underway to engage target physician groups, we expect to begin driving optimal adoption of Lymphoseek throughout the U.S.," Pykett added.
